Tag Archive for: remternetug

While the Alzheimer’s space awaits data from the Phase III trial of Eli Lilly’s donanemab, the company unveiled the first clinical data from another anti-amyloid antibody at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2023). 

Early data from the company’s first human study of its next-generation Alzheimer’s treatment showed that it lowered levels of toxic amyloid plaques in the brains of people in the earliest stages of the mind-wasting disease.

Eli Lilly isn’t having a good year in Alzheimer’s disease. Data released Wednesday from the Phase III A4 study showed solanezumab fell short of its primary endpoint, failing to slow cognitive decline in patients with preclinical Alzheimer’s disease. 

Following a banner year marked by the approval and launch of its diabetes drug Mounjaro, Eli Lilly revealed at the 41st J.P. Morgan Healthcare Conference that it was preparing for another big year.